Logotype for Processa Pharmaceuticals Inc

Processa Pharmaceuticals (PCSA) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Processa Pharmaceuticals Inc

Q3 2026 earnings summary

13 Nov, 2026

Executive summary

  • July acquisition of Vidya added VT-7208, a BTK inhibitor targeting food allergy, CSU and relapsing MS; $200.0M gross private placement accompanied the transaction.

  • Q3 net loss was $183.2M, driven mainly by a $178.0M acquired in-process R&D charge with no alternative future use.

Financial highlights

  • Q3 2026 R&D was $1.8M vs. $1.7M YoY; G&A was $4.3M vs. $1.8M; operating loss was $184.1M vs. $3.5M.

  • 9M 2026 net loss was $189.8M vs. $10.2M YoY; operating loss was $189.8M vs. $10.3M, including $178.0M acquired IPR&D expense.

  • Q3 basic and diluted loss per share was $61.58 vs. $1.81; 9M loss per share was $68.18 vs. $10.48.

  • No product revenue; 9M operating cash use was $10.8M vs. $8.5M, while cash and equivalents reached $180.2M at September 30.

Outlook and guidance

  • Net proceeds of $187.1M from the private placement are intended to fund operations into H2 2029 and through VT-7208 Phase 2 proof-of-concept milestones.

  • Food allergy Phase 2 initiation targeted H2 2026, with PoC data H2 2027; CSU initiation H2 2026 and data H1 2028; relapsing MS initiation H1 2027 and data H2 2028.

  • Clinical trial costs were expected to rise in H2 2026 as three VT-7208 Phase 2 trials advance; operating cash flows are expected to remain negative for the foreseeable future.

  • Management expects cash to fund planned operations for at least 12 months, but substantial doubt about going concern remains due to conditional preferred-stock conversion and potential cash settlement.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Processa Pharmaceuticals